Clinical Trials Browser

Phase 1/2 × Recurrence × rilotumumab × Clear all

NCT01233687 2017-06-22

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

Phase 1/2 Completed

49 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Recurrence